Sage Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Sage Therapeutics announced a significant reduction in net losses and substantial revenue growth for the second quarter and first half of 2025, driven by ZURZUVAE commercialization, while navigating a pending acquisition by Supernus Pharmaceuticals and ongoing legal challenges.
Sage Therapeutics reports a net loss of $62.2 million for Q1 2025, focusing on ZURZUVAE commercialization and pipeline development.
Sage Therapeutics reported its Q3 2024 financial results, highlighting the commercial progress of ZURZUVAE for postpartum depression and a strategic reorganization to prioritize key programs.
Sage Therapeutics' Q2 2024 results highlight ongoing commercialization of ZURZUVAE for postpartum depression and continued pipeline development, particularly for dalzanemdor.
Sage Therapeutics reported its first quarter 2024 results, highlighting the commercial launch of ZURZUVAE for postpartum depression and ongoing clinical trials for other brain health therapies.